安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Geron | Working to change the course of blood cancers
Geron is tirelessly pursuing blood cancer treatments with the potential to extend and enhance lives
- Geron Corporation - Investors Media
Geron is a commercial-stage biopharmaceutical company with a first-in-class telomerase inhibitor that is approved in the United States for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia
- Geron Corporation - Geron Announces FDA Approval of RYTELO™ (imetelstat . . .
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer Our first-in-class telomerase inhibitor RYTELO™ (imetelstat) is FDA-approved for the treatment of adult patients with lower-risk MDS with transfusion dependent anemia
- Advancing how blood cancers are treated | Geron
Geron is exploring the broad potential of telomerase inhibition across multiple hematologic malignancies
- Our tireless pursuit | Geron
With a seasoned leadership team with world-class expertise spanning research, clinical development, regulatory, manufacturing and commercial experience in hematologic malignancies, Geron is prepared to deliver on our mission to change lives by changing the course of blood cancer
- Geron Corporation Announces Departure of Chief Executive Officer
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that John “Chip” A Scarlett, M D , President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025
- Our story continues to evolve - Geron
For more than 30 years, Geron has tirelessly dedicated itself to the pursuit of new therapies for patients with blood cancers
- Geron Corporation - Geron Corporation Announces Up to $375 Million in . . .
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer Our first-in-class telomerase inhibitor RYTELO™ (imetelstat) is approved in the United States for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion dependent anemia
|
|
|